

# TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

NCT07487363

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Hudson Biotech
Enrollment	80 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Age 40-75 years, able to provide written informed consent.
- Documented stable ASCVD (e.g., prior myocardial infarction  $\geq 6$  months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease).
- On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening.
- Resting systolic blood pressure  $\leq 160$  mmHg and diastolic blood pressure  $\leq 100$  mmHg (with or without therapy).
- Able and willing to comply with study visits and procedures.

### Exclusion (10)

- Acute coronary syndrome, stroke/transient ischemic attack, or coronary revascularization within 6 months before screening.
- New York Heart Association (NYHA) class III-IV heart failure or left ventricular ejection fraction  $\leq 35\%$ .
- Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy.
- Severe renal impairment (eGFR  $\leq 30$  mL/min/1.73 m<sup>2</sup>) or end-stage renal disease.
- Clinically significant hepatic impairment (e.g., Child-Pugh class B/C) or ALT/AST  $\geq 3$ x upper limit of normal at screening.
- ... and 5 more (see full listing online)

## Locations (1 total)

---

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China